Therapeutic benefit of the most expensive drugs covered by Medicare and Medicaid
Open Access
- 1 October 2025
- journal article
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 18 (1) , 2564405
Abstract
The United States began drug pricing negotiations in 2024 under the Affordable Care Act. Evaluating the therapeutic benefit of drugs will help guide pricing decisions and are an opportunity to improve healthcare affordability. We conducted a cross-sectional study of the 50 most expensive drugs by dosage unit covered by Medicare Part B, Medicare Part D, and Medicaid in 2022. We reported their level of clinical benefit as evaluated by health technology assessment agencies in France and Germany, their level of innovation as rated by the Food and Drug Administration of the United States, and their safety and effectiveness ratings as measured by Prescrire International, an independent French organisation that evaluates medicines. Our study found that among the 50 most expensive drugs in the U.S. covered by Medicare and Medicaid in 2022, 28 (56%) were rated by French and German HTAs as having low therapeutic benefit and most (n = 20; 40%) were rated by Prescrire International as having poor effectiveness-safety ratings. Almost all (n = 48; 96%) drugs were ineligible under current exclusion criteria for price negotiations. Many of the most expensive drugs were rated as having low added clinical benefit. As the US begins price negotiations under the Inflation Reduction Act, understanding the clinical value of drugs may help inform debates over drug affordability.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (T35DK104689)
- Arnold Ventures
- Agency for Healthcare Research and Quality
- Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation
- Swiss National Science Foundation
- Yale-Mayo Clinic Center for Excellence in Regulatory Science and Innovation (CERSI) program
- Stravros Niarchos Foundation
This publication has 10 references indexed in Scilit:
- Therapeutic Value of Orphan Drugs Approved by Health Canada: A Cross-Sectional StudyJournal of General Internal Medicine, 2024
- Added Therapeutic Benefit of Top-Selling Brand-name Drugs in MedicareJAMA, 2023
- Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021JAMA Health Forum, 2022
- Trends in Within-Class Changes in US Average Wholesale Prices for Brand-Name Medications for Common Conditions From 2015 to 2020JAMA Network Open, 2021
- Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort studyBMJ, 2020
- Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysisThe Lancet Oncology, 2020
- US drug marketing: how does promotion correspond with health value?BMJ, 2017
- How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort StudyHealthcare Policy, 2016
- An Improved Approach To Measuring Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011Health Affairs, 2013
- Medication Costs, Adherence, And Health Outcomes Among Medicare BeneficiariesHealth Affairs, 2003